Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structure-Informed Design of an Enzymatically Inactive Vaccine Component for Group A <i>Streptococcus</i>

7 Aug 2013

Abstract excerpt

UNLABELLED: Streptococcus pyogenes (group A Streptococcus [GAS]) causes ~700 million human infections/year, resulting in >500,000 deaths. There is no commercial GAS vaccine available. The GAS surface protein arginine deiminase (ADI) protects mice against a lethal challenge. ADI is an enzyme that converts arginine to citrulline and ammonia. Administration of a GAS vaccine preparation containing wild-type ADI, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimicrobial Peptides and Activities
Share to Orthopedic Infections and Treatments
Share to Streptococcal Infections and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23919999
DOI: 10.1128/mbio.00509-13

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structure-Informed Design of an Enzymatically Inactive Vaccine Component for Group A <i>Streptococcus</i>PMID 23919999Read ↗

Multiepitope-based vaccine design against DiiA in <i>Streptococcus pneumoniae</i> , An immunoinformatics approachSemantic proximity Read ↗

Update on the development of Group A Streptococcus vaccinesSemantic proximity Read ↗

Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococciSemantic proximity Read ↗

Epitope-Based Multimeric Subunit Vaccine (ATOMSSUISpenta) Confers Cross-Protection Against Streptococcus suis InfectionSemantic proximity Read ↗

Novel Conserved Group A Streptococcal Proteins Identified by the Antigenome Technology as Vaccine Candidates for a Non-M Protein-Based VaccineSemantic proximity Read ↗

The <i>Streptococcus agalactiae</i> R3 surface protein is encoded by <i>sar5</i>Semantic proximity Read ↗

Immunoinformatics-aided design of a new multi-epitope vaccine adjuvanted with domain 4 of pneumolysin against Streptococcus pneumoniae strainsSemantic proximity Read ↗

The Group A Streptococcal Vaccine Candidate VAX-A1 Protects against Group B Streptococcus Infection via Cross-Reactive IgG Targeting Virulence Factor C5a PeptidaseSemantic proximity Read ↗

Molecular biology of Group A Streptococcus and its implications in vaccine strategies.Semantic proximity Read ↗

Reverse and structural vaccinology approach to design a highly immunogenic multi-epitope subunit vaccine against Streptococcus pneumoniae infection.Semantic proximity Read ↗

Site-Specific Conjugation of Cell Wall Polyrhamnose to Protein SpyAD Envisioning a Safe Universal Group A Streptococcal VaccineSemantic proximity Read ↗

Structure, Regulation, and Putative Function of the Arginine Deiminase System of<i>Streptococcus suis</i>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.